Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: Mechanisms of action of otilonium bromide

Therapeutic Advances in Gastroenterology

Volumn 7, Issue 4, 2014, Pages 156-166

  Rychter, Jakub ^a   Espen, Francisco ^b   Gallego, Diana ^b   Vergara, Patri ^b   Jimenez, Marcel ^b   Clave, Pere ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

gastrointestinal motility; irritable bowel syndrome; L type calcium channel; otilonium bromide; smooth muscle relaxants; spasmolytics; tachykinin receptor; visceral sensitization

Indexed keywords

CALCIUM; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; MUSCARINIC RECEPTOR; NEUROTRANSMITTER; NICOTINIC RECEPTOR; OTILONIUM BROMIDE; TACHYKININ RECEPTOR;

ABDOMINAL CRAMP; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; COLON MOTILITY; DIVERTICULOSIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INTESTINE MUSCLE; IRRITABLE COLON; MOTONEURON; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; SMOOTH MUSCLE TONE; VISCERAL PAIN;

EID: 84904810839     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X14525250     Document Type: Review

References (53)

1. Auli M. Martinez E. Gallego D. Opazo A. Espin F. Marti-Gallostra M. et al. (2008) Effects of excitatory and inhibitory neurotransmission on motor patterns of human sigmoid colon in vitro. Br J Pharmacol 155: 1043–1055.
2. Bampton P. Dinning P. (2013) High resolution colonic manometry – what have we learnt? A review of the literature 2012. Curr Gastroenterol Rep 15: 328.
3. Battaglia G. Morselli-Labate A. Camarri E. Francavilla A. de Marco F. Mastropaolo G. et al. (1998) Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 12: 1003–1010.
4. Beyder A. Farrugia G. (2012) Targeting ion channels for the treatment of gastrointestinal motility disorders. Therap Adv Gastroenterol 5: 5–21.
5. Boeckxstaens G. Corazziari E. Mearin F. Tack J. (2013) IBS and the role of otilonium bromide. Int J Colorectal Dis 28: 295–304.
6. Chang F. Lu C. Luo J. Chen T. Chen M. Chang H. (2011) The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil 17: 402–410.
7. Chey W. Jin H. Lee M. Sun S. Lee K. (2001) Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 96: 1499–1506.
8. Cipriani G. Santicioli P. Evangelista S. Maggi C. Riccadonna S. Ringressi M. et al. (2011) Effect of otilonium bromide and ibodutant on the internalization of the NK 2 receptor in human colon. Neurogastroenterol Motil 23: 96–102.
9. Clave P. Acalovschi M. Triantafillidis J. Uspensky Y. Kalayci C. Shee V. et al. (2011) Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 34: 432–442.
10. Costa M. Brookes S. Steele P. Gibbins I. Burcher E. Kandiah C. (1996) Neurochemical classification of myenteric neurons in the guinea-pig ileum. Neuroscience 75: 949–967.
11. Czimmer J. Suto G. Kiraly A. Mozsik G. (2001) Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. J Physiol Paris 95: 153–156.
12. Dinning P. Wiklendt L. Gibbins I. Patton V. Bampton P. Lubowski D. et al. (2013) Low-resolution colonic manometry leads to a gross misinterpretation of the frequency and polarity of propagating sequences: initial results from fiber-optic high-resolution manometry studies. Neurogastroenterol Motil 25: 640–649.
13. Drossman D. Camilleri M. Mayer E. Whitehead W. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123: 2108–2131.
14. Evangelista S. (2004) Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 10: 3561–3568.
15. Evangelista S. Cochet P. Bromet N. Criscuoli M. Maggi C.A., (2000) A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos 28: 643–647.
16. Evangelista S. Giachetti A. Chapelain B. Neliat G. Maggi C. (1998) Receptor binding profile of otilonium bromide. Pharmacol Res 38: 111–117.
17. Forte E. Pizzoferrato M. Lopetuso L. Scaldaferri F. (2012) The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. Eur Rev Med Pharmacol Sci 16: 25–37.
18. Furness J. Sanger G. (2002) Intrinsic nerve circuits of the gastrointestinal tract: identification of drug targets. Curr Opin Pharmacol 2: 612–622.
19. Gallego D. Auli M. Aleu J. Martinez E. Rofes L. Marti-Rague J. et al. (2010) Effect of otilonium bromide on contractile patterns in the human sigmoid colon. Neurogastroenterol Motil 22: e180–e191.
20. Gallego D. Espin F. Mikulka J. Smirg O. Gil V. Faundez-Zanuy M. et al. (2013) In vitro motor patterns and electrophysiological changes in patients with colonic diverticular disease. Int J Colorectal Dis 28: 1413–1422.
21. Gandia L. Villarroya M. Lara B. Olmos V. Gilabert J. Lopez M. et al. (1996) Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Br J Pharmacol 117: 463–470.
22. Gibbons S. Strege P. Lei S. Roeder J. Mazzone A. Ou Y. et al. (2009) The alpha1H Ca2+ channel subunit is expressed in mouse jejunal interstitial cells of Cajal and myocytes. J Cell Mol Med 13: 4422–4431.
23. Hirota C. McKay D. (2006) Cholinergic regulation of epithelial ion transport in the mammalian intestine. Br J Pharmacol 149: 463–479.
24. Holzer P. Holzer-Petsche U. (1997) Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 73: 173–217.
25. Holzer P. Holzer-Petsche U. (2001) Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 1: 583–590.
26. Huizinga J. Farraway L. Den Hertog A. (1991) Effect of voltage and cyclic AMP on frequency of slow-wave-type action potentials in canine colon smooth muscle. J Physiol 442: 31–45.
27. Jung H. Choung R. Locke G. 3rd Schleck C. Zinsmeister A. Talley N. (2010) Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol 105: 652–661.
28. Lee H. Hennig G. Fleming N. Keef K. Spencer N. Ward S. et al. (2007) The mechanism and spread of pacemaker activity through myenteric interstitial cells of Cajal in human small intestine. Gastroenterology 132: 1852–1865.
29. Lindqvist S. Hernon J. Sharp P. Johns N. Addison S. Watson M. et al. (2002) The colon-selective spasmolytic otilonium bromide inhibits muscarinic M (3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol 137: 1134–1142.
30. Lovell R. Ford A. (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712–721.
31. Maggi C. (1997) Tachykinins as peripheral modulators of primary afferent nerves and visceral sensitivity. Pharmacol Res 36: 153–169.
32. Maggi C. Manzini S. Meli A. (1983) Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization. Arch Int Pharmacodyn Ther 264: 305–323.
33. Marger F. Gelot A. Alloui A. Matricon J. Ferrer J. Barrere C. et al. (2011) T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc Natl Acad Sci U S A 108: 11268–11273.
34. Martin M. Hove-Madsen L. Jimenez M. (2004) Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon. Neurogastroenterol Motil 16: 175–183.
35. Martinez-Cutillas M. Gil V. Gallego D. Mane N. Martin M. Jimenez M. (2013) Mechanisms of action of otilonium bromide (OB) in human cultured smooth muscle cells and rat colonic strips. Neurogastroenterol Motil 12: 803–812.
36. Mendelowitz D. Reynolds P. Andresen M. (1995) Heterogeneous functional expression of calcium channels at sensory and synaptic regions in nodose neurons. J Neurophysiol 73: 872–875.
37. Narducci F. Bassotti G. Granata M. Pelli M. Gaburri M. Palumbo R. et al. (1986) Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide. Dig Dis Sci 31: 241–246.
38. Qian A. Song D. Li Y. Liu X. Tang D. Yao W. et al. (2013) Role of voltage gated Ca2+ channels in rat visceral hypersensitivity change induced by 2,4,6-trinitrobenzene sulfonic acid. Mol Pain 9: 15.
39. Rao S. Sadeghi P. Beaty J. Kavlock R. Ackerson K. (2001) Ambulatory 24-h colonic manometry in healthy humans. Am J Physiol Gastrointest Liver Physiol 280: 629–639.
40. Sanders K. (2000) Postjunctional electrical mechanisms of enteric neurotransmission. Gut 47(Suppl. 4): 23–25.
41. Sanders K. (2008) Regulation of smooth muscle excitation and contraction. Neurogastroenterol Motil 20(Suppl. 1): 39–53.
42. Santicioli P. Zagorodnyuk V. Renzetti A. Maggi C. (1999) Antimuscarinic, calcium channel blocker and tachykinin NK 2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon. Naunyn Schmiedebergs Arch Pharmacol 359: 420–427.
43. Sarna S. (2006) Molecular, functional, and pharmacological targets for the development of gut promotility drugs. Am J Physiol Gastrointest Liver Physiol 291: 545–555.
44. Shin B. Kim J. Kim J. Hu S. Kim H. Hong S. et al. (2008) Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats. Arch Pharm Res 31: 117–124.
45. Smirnov S. Zholos A. Shuba M. (1992) Potential-dependent inward currents in single isolated smooth muscle cells of the rat ileum. J Physiol 454: 549–571.
46. Spiller R. (2012) Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 30: 64–69.
47. Strege P. Evangelista S. Lyford G. Sarr M. Farrugia G. (2004) Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol Motil 16: 167–173.
48. Strege P. Sha L. Beyder A. Bernard C. Perez-Reyes E. Evangelista S. et al. (2010) T-type Ca(2+) channel modulation by otilonium bromide. Am J Physiol Gastrointest Liver Physiol 298: 706–713.
49. Sutton J. Kilminster S. Mould G. (1997) The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Eur J Clin Pharmacol 52: 365–369.
50. Tobin G. Giglio D. Lundgren O. (2009) Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 60: 3–21.
51. Toulouse M. Coelho A. Fioramonti J. Lecci A. Maggi C. Buéno L. (2000) Role of tachykinin NK 2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 129: 193–199.
52. Wood J. Alpers D. Andrews P. (1999) Fundamentals of neurogastroenterology. Gut 45(Suppl. 2): 6–16.
53. Xiong Z. Sperelakis N. Noffsinger A. Fenoglio-Preiser C. (1995) Ca2+ currents in human colonic smooth muscle cells. Am J Physiol 269: 378–385.